[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"AUSL Romagna Rimini\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":100},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100627845","blue-light-for-donor-site-healing-in-burn-patients-100627845",false,"NCT07453927","Blue Light for Donor Site Healing in Burn Patients","Blue Light in the Treatment of Donor Site in Burn Patient: a Controlled Clinical Trial","CGU01_BL","Inclusion Criteria:\n\n* Patients with intermediate-deep burns with Total Body Surface Area (TBSA) \\> 10% requiring surgical treatment with escharectomy, presenting at least two Donor Site.\n* Patients over 18 years of age;\n* Patients who have signed the informed Consent Form (ICF) and understood the purpose of the study, or, if unable to give consent personally due to their condition, their legal guardian.\n\nExclusion Criteria:\n\n* Intermediate-deep burns TBSA \\\u003C 10% or superficial burns;\n* Patients under the age of 18;\n* Patients who are participating in other clinical trials with drugs or medical devices;\n* Patients with neoplasms or other conditions requiring the use of cytostatic or immunosuppressive drugs;\n* Patients with conditions that induce skin photosensitivity;\n* Pregnant or breastfeeding women;\n* Patients or relatives who are unable to understand the purposes of the trial;","ALL","18 Years",{"count":20,"type":21},25,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn whether blue light (BL) photobiomodulation can improve the healing of donor site (DS) wounds in patients with burn injuries who are treated surgically. This study will investigate whether adding BL therapy to the usual treatment can improve healing and patient outcomes in adult patients with intermediate and deep burns.\n\nThe main questions it aims to answer are:\n\n* Does the use of BL therapy combined with standard treatment reduce the healing time of DS compared with standard treatment alone?\n* Does BL therapy improve wound conditions, reduce pain, and decrease signs of infection during the healing process?\n* Is BL therapy safe and well tolerated when applied to DS?\n* Does the treatment improve the long-term quality of the scar after healing?\n\nResearchers will compare DS areas treated with standard care alone to DS areas treated with standard care plus BL therapy to see whether BL improves healing outcomes. Each participant will serve as their own comparison: two different DS areas on the same patient will receive the two different treatments.\n\nParticipants will:\n\n* Receive the standard treatment for DS, which includes routine wound care and dressing\n* Receive BL therapy on one DS area in addition to the standard treatment, while another DS area will receive standard treatment alone\n* Attend regular clinical evaluations where clinicians will assess wound healing and the condition of the wound bed\n* Report their pain levels using a simple numeric scale during the healing period\n* Undergo skin swabs to detect possible signs of infection\n* Be monitored for any local side effects, such as redness, burning sensation, warmth, itching, or skin irritation related to the light treatment\n\nAfter the DS have completely healed, participants will return for follow-up visits at 1 month and 3 months. During these visits, researchers will evaluate the quality of the scars and monitor for any late side effects.",[27,28,29,30],"Donor Site Complication","Burn","Photobiomodulation Therapy","Blue Light",[32,33,34,35,36],"donor site","burns","photobiomodulation","blue light","healing","RECRUITING","2026-03-31",{"date":40,"type":41},"2026-04-06","ACTUAL",{"date":43,"type":41},"2025-09-29",{"date":45,"type":21},"2026-09-28",{"name":47,"class":48},"AUSL Romagna Rimini","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":58,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":49},"100608504","espb-vs-intrathecal-morphine-for-assessements-of-quality-of-recovery-after-cesarean-section-100608504","NCT07202416","ESPB vs Intrathecal Morphine for Assessements of Quality of Recovery After Cesarean Section","Comparison of Erector Spinae Plane Block and Intrathecal Morphine for Assessements of Quality of Recovery After Caesarean Section: a Randomized Controlled Trial","BELLMERE","Inclusion Criteria:\n\n* Adult women aged 18-45 years\n* ASA physical status II-III\n* Full-term singleton pregnancy scheduled for elective cesarean section under spinal anesthesia\n\nExclusion Criteria:\n\n* ASA ≥ IV\n* Coagulation disorders\n* Emergency surgery\n* Preoperative infection (including infection at the ESPB puncture site)\n* Any contraindication to neuraxial analgesia\n* History of chronic pain\n* Use of opioids\n* Allergy to local anesthetics\n* Hypersensitivity to any drug used in the study\n* Inability to understand or use verbal pain assessment scales\n* Refusal to participate in the study","FEMALE","45 Years",{"count":61,"type":21},52,[24],"Cesarean section is a surgical procedure that involves significant pain, which is managed through a multimodal pharmacological approach.The primary objective of the study is to evaluate the quality of hospitalization after cesarean section using the QRo11 questionnaire in patients treated with a postoperative Erector Spinae Plane Block compared to those treated with intrathecal morphine.",[65,66],"Cesarean Section","Post Operative Pain",[65,68,69],"Erector Spinae plane block","Quality of recovery",{"date":71,"type":41},"2025-10-01",{"date":73,"type":41},"2025-06-18",{"date":75,"type":21},"2026-06",{"name":47,"class":48},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},"100507371","transfemoral-transcatheter-aortic-valve-implementation-at-hospital-without-on-site-cardiac-surgery-early-clinical-outcome-in-patients-with-prohibitive-surgical-risk-100507371","NCT05886517","Transfemoral Transcatheter Aortic Valve Implementation at Hospital Without On-site Cardiac Surgery: Early Clinical Outcome in Patients With Prohibitive Surgical Risk.","Inclusion Criteria:\n\n* Senile degenerative aortic valve stenosis with echocardiography derived criteria: mean gradient \\> 40 mmHg or jet velocity \\> 4.0 m\u002Fs aortic valve area (AVA) of \\\u003C 0.8 cm2 (or AVA index \\\u003C 0.5 cm2\u002Fm2)\n* Symptomatic due to aortic valve stenosis as demonstrated by NYHA Functional Class \\> = II\n* Age \\>= 75 years old\n* Patients with prohibitive risk established in the Heart Team and defined on the basis of the following clinica instrument criteria according with the Varc-2 consensus.\n* High surgical risk (%, logES\\>20%, EuroSCORE II \\> 9 and STS score \\> 8%)\n* Porcelain aorta (heavy circumferential calcification or severe atheromatous plaques that do not allow clamping.\n* Hostile chest (abnormal chest wall anatomy due to severe kyphoscoliosis or other skeletal abnormalities, complications form to previous surgery, evidence of severe radiotion damege, history of multiple recurrent pleural effusions causing internal adhesions.\n* Fragilty (slowness, weakness, exhaustion, wasting and malnutrition, poor endurance and inactivity, loss of independence, BMI \\\u003C 20 Kg\u002Fm2 and or weight loss 5 kg\u002Fyear, serum albumin \\\u003C 3,5 g\u002Fdl, cognitive impairment or dementia)\n* Severe liver disease\u002Fcirrosis\n* Presence of a patent graft of an internal mammary artery crossing mildline and\u002For adherent to posterior table of sternum\n* Severe pulmoary hypertension\n* Severe right ventricular dysfunction\n* Transfemoral access allowed\n* Signature of informed consent\n\nExclusion Criteria:\n\n* Tavi in case of aortic valve bioprosthesis (TAVI valve-in valve)\n* controindication to femoral access\n* Bicuspid aortic valve\n* Instrumental characteristics, evaluated by angioTC, associated with an increased risk of major complications: severe left ventricle outflow tract or sub annular calcification, condition associated with an increased risk of rupture of the valve ring, presence of complex aortic plaques correlated with the possibility of dissection, valvular ring-coronary ostia distance \\\u003C 10 mm associated with a high probability of coronary obstruction, severe aortic root dilatation or out of range aortic annulus diameters for TAVI are not complatible for safe valve implatation.","75 Years","120 Years",{"count":86,"type":21},200,[24],"Study design: single arm, interventional and multicenter study. The objectives are evaluate Safety and efficacy of TAVI in Department of Cardiology without on site cardiac Surgery for symptomatic severe aortic valve stenosis by expert operator team, in patients with prohibitive surgical risk. For the pilot phase, 20 patients will be enrolled. For whole study, all consecutive patients undergoing TAVI in center without CS on site will be enrolled to reach a number of about 200 patients.",[90],"Aortic Stenosis","2025-02-19",{"date":93,"type":41},"2025-02-21",{"date":95,"type":41},"2023-05-01",{"date":97,"type":21},"2026-04",{"name":47,"class":48},4,""]